Keywords
How to Cite
Abstract
The physiology of breathing during sleep predisposes to the onset or worsening of breathing disorders in patients with metabolic syndrome (MS), even if their respiratory function remains relatively normal while awake. Respiratory pathology often causes insomnia, which further aggravates the impairment of the quality of life of patients. Long-term low-flow oxygen therapy and noninvasive assisted ventilation improve gas exchange during sleep but often do not improve sleep disturbances
References
Бабак C.JI. Дневная сонливость, нарушения сна и ночная дыхательная недостаточность в практике терапевта // Consilium Medicum. 2006. - Т. 4, № 9.
Вейн A.M. Медицина сна // Избранные лекции по неврологии; под ред. проф. В.Л. Голубева. М.: Эйдос Медиа, 2006. - С. 12-20.
Ковальзон В.М., Стрыгин К.Н. Нейрохимические механизмы регуляции сна и бодрствования: роль блокаторов гистаминовых рецепторов в лечении инсомнии. Эффективная фармакотерапия. Неврология и психиатрия. Спецвыпуск «Сон и его расстройства», 2013, 12: 8-15.
Dubey AK, Handu SS, Mediratta PK. Suvorexant: the first orexin receptor antagonist to treat insomnia. J Pharmacol Pharmacother. 2015;6(2):118-121.
Krystal AD, Benca RM, Kilduff TS. Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system. J Clin Psychiatry. 2013;74(1):3-20.
Marin JM, Carrizo SJ. Overlap syndromes of sleep and breathing disorders. In: Kryger M.H., Roth T., Dement W.C. (eds.) Principles and practice of sleep medicine. 6-th ed. Philadelphia: Elsevier; 2017.
Michael ML. Etiology and Pathophysiology of Insomnia. (In Principles and practice of sleep medicine. Kryger M, Roth T, Dement WC, eds.). Elsevier, Inc.: Philadelphia, 2016: 769-784.